We are delighted to be part of this year's @BIODeutschland yearbook (in German) and to support the publication with a guest article on “25 years of Targeted Radionuclide Therapy research in Germany” by our CEO, Steffen Schuster. Take a look on page 56 & 57!

This year, our annual Christmas donation supports the German Cancer Research Center (DKFZ). Preventing cancer, detecting it earlier & treating it better - these are the goals that scientists at the largest biomedical research institution in Germany are working towards.

We are grateful for our accomplishments in 2022 and look forward to what the future holds. The holiday season is a good opportunity to pause & recharge our batteries for next year. We wish you and your loved ones a peaceful and relaxing holiday season & success for the #NewYear.

Connect with ITM’s CEO Steffen Schuster and CFO Dr. Klaus Maleck at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Steffen Schuster will be presenting a corporate overview on Monday, Jan 9 at 8:00 am PST. Read full press release at: bit.ly/3GAQRJG

Die Behandlung des bayernweit ersten Patienten mit dem in Europa neu zugelassenen Medikament ist ein weiterer wichtiger Meilenstein in der #Therapie von fortgeschrittenem #Prostatakrebs. Mit unserem Know-how & als Zulieferer von Lutetium-177 leisten auch wir unseren Beitrag dazu.

Two days until #WorldCancerDay! Join ITM for the official #5kChallenge to stand up for cancer patients by completing 5km – whether it’s walking, running or cycling. Are you in? Then track your results with your fitness tracker and let us know! 🏃‍🚴

Today we announced the start of a phase I clinical trial with our radiotherapeutic drug candidate ITM-31. A novel Targeted Radionuclide Therapy candidate with non-carrier-added lutetium-177 for the treatment of malignant glioblastoma. More at: bit.ly/3JgCsT8

Today, we celebrate #WorldTheranosticsDay and the ongoing innovation and advancement in the field of #theranostics and honor Dr. Saul Hertz for his achievements. Learn more about Theranostics in the video below 👇

Exciting news! ITM has reached more than 500 employees as of April! 🎉 Join our team and help shape the future of Targeted Radionuclide Therapy. Apply now and be a part of our mission to revolutionize cancer treatment: bit.ly/41e2MF5 #radiopharmaceuticals #wearehiring

Today we announced that ITM has #opened its U.S. #headquarters in #Princeton, New Jersey and appointed Roger Estafanos as U.S. General Manager. Read more at: bit.ly/41QRIht

Today we announced that ITM has entered into a cooperation agreement with the Paul Scherrer Institute (PSI) for the implementation of upscaled manufacturing of a novel therapeutic radionuclide, terbium-161. Read more at: bit.ly/3Lyp5jt

📅 Connect with ITM’s CFO Dr. Klaus Maleck at #Jefferies Healthcare Conference in New York on Wednesday, June 7, 2023. Looking forward to meeting you and many valuable discussions. More about us at: itm-radiopharma.com

📣 Exciting news! ITM announced equity investment round of €255m, plans to Advance #Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities. Read more at: bit.ly/3NcAXIM

ITM Opened World's Largest Lutetium-177 Production Facility for #TargetedRadionuclideTherapies Against Cancer. 🌟🌍🩺 Read the full press release here: bit.ly/3oXoeAD

📅 ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023. For more information, please see our full press release here: bit.ly/42WVlCF

Today we announced the expansion of the global #supply #agreement with @PointBiopharma signed in 2020 to cover the clinical and potential future commercial development of the lutetium-177-based molecules in POINT’s development pipeline. Read more at: bit.ly/47eW05u

🌟Farewell to an unforgettable EANM Congress 2023! Thanks to all attendees, speakers and exhibitors for making it remarkable. Let's carry the inspiration forward and continue driving excellence in #nuclearmedicine!🚀 #EANMConference #EANM23 #radiopharmaceuticals #theranostics

Today we announced the launch of Actineer Inc., a new joint venture in the global production of Actinium-225 with our partner, CNL | LNC. Our company will address the unmet global manufacturing & production needs of this coveted radioisotope. Read more at: itm-radiopharma.com/news/press-rel…